Cargando…
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
INTRODUCTION: We previously reported an association between tumor-specific 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) expression and a good prognosis in breast cancer. Here, the predictive value of HMG-CoAR expression in relation to tamoxifen response was examined. METHODS: HMG-CoAR...
Autores principales: | Brennan, Donal J, Laursen, Henriette, O'Connor, Darran P, Borgquist, Signe, Uhlen, Mathias, Gallagher, William M, Pontén, Fredrik, Millikan, Robert C, Rydén, Lisa, Jirström, Karin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109580/ https://www.ncbi.nlm.nih.gov/pubmed/21281480 http://dx.doi.org/10.1186/bcr2820 |
Ejemplares similares
-
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
por: Borgquist, Signe, et al.
Publicado: (2008) -
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
por: Bengtsson, Erik, et al.
Publicado: (2014) -
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer
por: Brennan, Donal J, et al.
Publicado: (2010) -
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients
por: Gustbée, Emma, et al.
Publicado: (2015) -
Predictive Modeling
of HMG-CoA Reductase Inhibitory
Activity and Design of New HMG-CoA Reductase Inhibitors
por: Samizo, Shigeyoshi, et al.
Publicado: (2023)